Delivering a potent cancer drug with nanoparticles can lessen side effects
The new nanoparticle, which delivers the drug in a form activated when it reaches its target, also treats tumors more effectively than the unadorned drug in mice.
On the trail of a stealthy parasite
Biologist Jeroen Saeij shows why some strains of Toxoplasma are more dangerous than others.
Countering ‘memory loss’ in the immune system
New findings from MIT biologists could help vaccine designers elicit long-term immunity.
The code for survival
Cells fight stress by reprogramming a system of RNA modifications, researchers find.
Jaenisch to receive MGH's Warren Triennial Prize
Whitehead member, biology professor wins prize alongside Kyoto University professor.
Suresh discusses the role of engineering in the study of infectious disease
In public lecture at MIT, former dean describes progress in understanding malaria.
Team wins protein-folding prize
Earn $5,000 for top finish in the University Protein Folding Challenge
3 Questions: Sara Seager on the discovery of a ‘new’ form of life
The MIT planetary scientist discusses what the finding means for life on Earth and elsewhere in the universe.
When gender isn’t written all over one’s face
Neuroscientists find that the same face may look male or female, depending on where it appears in a person’s field of view.
Timing is everything for cancer protein p53
Biologists find that restoring the gene for p53 can slow the spread of advanced lung tumors, but doesn’t help early-stage cancers.
Lindquist receives National Medal of Science
President Obama presents nation’s top science awards at White House ceremony Wednesday.
Turning off cancer genes
RNA interference holds much promise as a cancer treatment, but technical challenges remain.
A better way to target tumors
In spite of slow progress toward targeting cancer drugs to individual patients, hope remains.
Tuning in to a new hearing mechanism
Findings from MIT scientists could lead to hearing aids that mimic the ear’s ability to focus on particular frequencies.
A new target for cancer drugs
Shutting down an enzyme that responds to DNA damage could boost the effects of traditional chemotherapy.